Life Technologies Corporation (LIFE) recently launched its GeneArt Algae Engineering Kits for photosynthetic microalgae Chlamydomonas reinhardtii and Synechococcus elongatus. These GeneArt Chlamydomonas Engineering Kits and GeneArt Synechoccus Engineering Kits help create the first standardized system for algae research and metabolic engineering.
The algal strains in the kits are model organisms for the study of photosynthesis, circadian rhythms and nutrient-regulated gene activity. These are used for bioproduction of biofuels, nutraceuticals and specialty chemicals are the first that can be stored frozen at -80 degrees Celsius.
Life Technologies is confident about the strong potentials of the GeneArt kits, which should enhance the company’s algae research to a level when it ought to personify work with yeast and E. coli. With the kits researchers will be able to create transformed algal cells into standardize experiments with genetically consistent frozen cell stocks within a small period of time.
Life Technologies enjoys a strong position in the life sciences market. Over the past few years, Life Technologies has been expanding its product portfolio through acquisitions and new product launches. The company views immense potential in applied markets where technologies can help in carrying out biological research in fast growing industries such as forensics, food and water testing. Over the next few years, Life’s focus on developing industry-leading franchises in high-growth technology areas, applied markets and emerging geographies will be the key drivers for long-term growth.
However, Life Technology’s performance is thwarted by a sustained slowdown in government and academic research funding. Although the company does not expect the scenario to worsen in the near future, it is repositioning itself for a slower growth environment by lowering its cost structure and increasing its focus on R&D initiatives.
Challenges, also remain in the form of tighter budgets for academic and government funded research in both the US and Europe, a trend that is expected to continue. The company faces stiff competition from players such as Illumina (ILMN) and Qiagen (QGEN).
We are currently Neutral on the stock, in line with Qiagen. Both stocks carry short term Zacks #3 Ranks (Hold).
ILLUMINA INC (ILMN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment